Hong Kong IVM (In Vitro Maturation) Detailed Guide: Suitable Candidates & Full Treatment Process
Hong Kong IVM (In Vitro Maturation) is primarily suitable for patients with Polycystic Ovary Syndrome (PCOS) and those sensitive to ovulation induction medications. From a reproductive specialist's perspective, this article explains IVM technology principles, treatment流程, suitable candidates, precautions, and differences between Hong Kong and Mainland China, helping patients understand the real-world applications and decision-making considerations of this technology.
Main text begins
Author: Reproductive Specialist ｜ Reviewer: Reproductive Medicine Editor ｜ Updated: 2025
IVM from a Clinical Decision-Making Perspective: When Would I Recommend Patients Consider It
In my reproductive clinic, patients with PCOS (Polycystic Ovary Syndrome) account for over 30% of my consultations. These patients face a classic dilemma: they have a high number of antral follicles in their ovaries, but their response to ovulation induction medications is unpredictable—either insufficient or excessive, with the latter potentially leading to Ovarian Hyperstimulation Syndrome (OHSS). When a patient with AMH > 6.8 ng/mL, antral follicle count > 30, a history of OHSS, or significant discomfort with ovulation induction medications sits before me, IVM (In Vitro Maturation) enters my decision-making options.
IVM is not a new technology, but its clinical application has been relatively conservative. Its core logic is: retrieve immature oocytes before the follicles have matured, complete in vitro maturation under a specific laboratory culture system, and then perform ICSI for fertilization. The greatest advantage of this is that it can almost completely avoid OHSS while significantly reducing the amount of ovulation induction medications used. However, the trade-off is clear—pregnancy rates are generally lower than conventional IVF, and it requires higher standards for embryology lab hardware and personnel experience. Currently, 3-4 fertility centers in Hong Kong routinely perform IVM, with technical protocols and culture systems largely aligned with leading international centers.
IVM Technology Directly Explained: What It Is and How Effective It Is
IVM stands for In Vitro Maturation. Simply put, it involves retrieving immature oocytes (at the GV or MI stage) from the ovaries, culturing them in a special laboratory medium for 24-48 hours to allow them to develop into mature oocytes (MII stage), then fertilizing them via ICSI to form embryos for transfer.
Regarding effectiveness, it needs to be viewed objectively:
- Live Birth Rate: In PCOS patients, the live birth rate per IVM transfer cycle is approximately 25%-35%, lower than the 40%-50% for conventional IVF (data from recent international IVM collaborative group statistics). However, the difference is mainly in the first transfer; cumulative pregnancy rates narrow the gap.
- OHSS Risk: Near zero. This is the core advantage of IVM. For individuals at high risk of OHSS, IVM is one of the safest options.
- Cycle Cancellation Rate: Approximately 10%-15%, mainly due to failure of oocyte maturation in vitro or no transferable embryos after fertilization.
How a Reproductive Specialist Views IVM: Its Clinical Application Positioning
Within the assisted reproductive technology system, IVM is considered a second- or third-line option. My reproductive medicine team positions IVM as follows:
- First-line Indications: PCOS with high OHSS risk, severe allergy or intolerance to ovulation induction medications, need for urgent fertility preservation (e.g., cancer patients)
- Second-line Indications: Previous conventional IVF cycles with asynchronous follicle development, very low oocyte yield or empty follicle syndrome, oocyte maturation disorders (certain types)
- Not Recommended: Diminished Ovarian Reserve (DOR), age > 38 years, recurrent implantation failure due to endometrial factors
Fertility centers in Hong Kong generally apply strict patient selection when using IVM. Each center has its own clinical pathway, but the consensus is that IVM success rates are highly dependent on patient age and ovarian reserve, followed by the laboratory's maturation culture system.
Regional Differences: Comparing Hong Kong IVM with Mainland China and Overseas
| Dimension | Hong Kong | Mainland China (Major Fertility Centers) | Overseas (Japan, Australia, Europe) |
|---|---|---|---|
| Number of Centers Offering | 3-4 | Approx. 15-20 (concentrated in Beijing, Shanghai, Guangzhou) | Japan ~30, Australia ~10, Europe ~50 |
| Culture System | Primarily commercial IVM media; some centers use self-prepared media | Mostly imported commercial culture media; a few centers have self-developed systems | Primarily commercial media; some Japanese centers use self-developed low-oxygen culture |
| Suitable Candidates | Primarily PCOS, strictly selected | Primarily PCOS; some centers extend to DOR (with poor outcomes) | Primarily PCOS; some European centers use it for fertility preservation |
| Average Treatment Cost | Approx. HKD 80,000-120,000 | Approx. RMB 30,000-60,000 | Japan ~JPY 800,000-1,200,000; Australia ~AUD 15,000-20,000 |
| Pregnancy Rate (PCOS Population) | 30%-35% per transfer cycle | 25%-32% per transfer cycle | 28%-38% per transfer cycle |
The advantage of Hong Kong IVM lies in its quality control system being aligned with international standards, high standardization of embryology labs, and strict regulation of medication use. The disadvantage is that treatment costs are significantly higher than in Mainland China, and patients need to bear their own travel and accommodation expenses.
Easily Overlooked Details: Key Points in IVM Treatment
In clinical practice, several details significantly impact IVM outcomes but are often overlooked by patients and even some doctors:
- Precision of Follicle Diameter Monitoring: The timing of oocyte retrieval for IVM differs from conventional IVF. Puncture is generally performed when follicles reach 10-14mm, not 18-22mm. Too early leads to low oocyte yield; too late, some follicles may have already initiated luteinization. It requires ultrasound specialists with specific IVM experience.
- Individualized Hormone Addition in Culture Media: Different patients' oocytes respond differently to factors like FSH, hCG, and EGF. Experienced embryologists adjust the culture protocol based on the morphology of the cumulus-oocyte complex and granulosa cell status. The degree of individualization in this step directly affects maturation rates.
- ICSI Timing: After in vitro maturation, the "fertilization window" of oocytes is narrower than that of in vivo matured eggs. ICSI should ideally be performed within 4-6 hours after observing the first polar body extrusion. Delay can reduce fertilization rates and embryo quality.
- Luteal Phase Support Protocol: In IVM cycles, due to the lower number and impaired function of granulosa cells, progesterone levels in the luteal phase are typically low. A stronger luteal phase support protocol is needed, such as intramuscular progesterone + oral dydrogesterone + vaginal micronized progesterone, and may require supplementation with hCG or GnRH-a.
Common Pitfalls: Frequent Patient Misunderstandings
As a practitioner, I observe several common misconceptions patients have about IVM:
- Myth 1: "IVM is more advanced than IVF, so it has a higher success rate." The reality is that IVM success rates are lower than conventional IVF. It addresses safety and medication tolerance, not improving pregnancy rates.
- Myth 2: "IVM involves no injections and is completely painless." Although IVM uses few or no ovulation induction medications, the oocyte retrieval puncture procedure is identical to conventional IVF—transvaginal ultrasound-guided puncture with associated risks and discomfort.
- Myth 3: "IVM is suitable for everyone with poor ovarian function." Quite the opposite. IVM has basic requirements for ovarian reserve—AMH should ideally be > 1.5 ng/mL, and antral follicle count > 8. Patients with diminished ovarian reserve using IVM tend to have low oocyte yield and maturation rates, leading to poor clinical outcomes.
- Myth 4: "IVM in Hong Kong is definitely better than in Mainland China." Hong Kong has strict medical quality control, but IVM success primarily depends on patient selection and the laboratory system. Some large fertility centers in Mainland China (e.g., Peking University Third Hospital, CITIC Xiangya, Renji Hospital) have comparable IVM experience at much lower costs. The choice of location requires comprehensive evaluation of the medical condition, financial situation, and schedule.
Actual Process: Full Steps of Hong Kong IVM Treatment
Below is the standard treatment process at a Hong Kong fertility center offering IVM. Minor variations may exist between centers:
- Initial Consultation & Assessment: Visit on day 2-4 of the menstrual cycle for transvaginal ultrasound, AMH, FSH, LH, E2, TSH, PRL, and other baseline tests, along with a semen analysis for the male partner. The doctor evaluates suitability for IVM.
- Protocol Formulation: Once IVM is confirmed, a "non-stimulation" or "mini-stimulation" protocol is typically used. Non-stimulation involves no ovulation induction medications. Mini-stimulation involves oral letrozole 2.5-5mg/day from cycle day 3-5 for 5 days, or low-dose FSH injections for 3-5 days.
- Follicle Monitoring: Starting from cycle day 7, transvaginal ultrasound is performed every 1-2 days to monitor follicle growth. When the leading follicle diameter reaches 10-14mm, hCG 5000-10000 IU or GnRH-a 0.2mg is administered to trigger resumption of oocyte meiosis.
- Oocyte Retrieval Surgery: 36-38 hours after hCG injection, under intravenous sedation, transvaginal ultrasound-guided puncture is performed to retrieve immature oocytes. The needle is slightly finer and suction pressure slightly lower than conventional IVF to minimize damage to the cumulus-oocyte complex.
- In Vitro Maturation Culture: In the lab, immature oocytes are identified and isolated under a stereomicroscope, placed in IVM culture medium, and incubated at 37°C, 6% CO2, 5% O2 for 24-48 hours. Maturation progress is checked every 8-12 hours.
- ICSI Fertilization: After observing first polar body extrusion (MII stage), ICSI is performed within 4-6 hours. Note: The zona pellucida of IVM-derived oocytes may be slightly harder, requiring adjustment of the ICSI needle penetration force.
- Embryo Culture & Transfer: After fertilization, embryos are cultured routinely to day 3 (cleavage stage) or day 5-6 (blastocyst stage). The number of embryos transferred depends on quality and patient condition, typically 1-2. Single embryo transfer is permitted in Hong Kong.
- Luteal Phase Support: Starting from the transfer day, a triple regimen of intramuscular progesterone + oral dydrogesterone + vaginal micronized progesterone is used, continuing until the pregnancy test 12-14 days after transfer. If pregnant, luteal support continues until 10-12 weeks of gestation.
Timeline: How Long Does IVM Treatment Take
| Stage | Time Required | Notes |
|---|---|---|
| Initial Assessment | 1 day (can be completed in one visit) | Recommended on cycle day 2-4 |
| Follicle Monitoring Period | 7-12 days | Frequency adjusted based on follicle growth rate |
| Oocyte Retrieval Surgery | 1 day (surgery + 2-hour post-op observation) | Plan for half to one day of rest |
| In Vitro Maturation + ICSI + Embryo Culture | 3-6 days | Similar timeline to conventional IVF |
| Embryo Transfer | 1 day | Bed rest for 30 minutes post-transfer is sufficient |
| Pregnancy Test | 12-14 days after transfer | Blood test for β-hCG |
| Total Cycle Duration | Approx. 4-6 weeks | Excluding pre-cycle preparation and follow-up |
If planning a frozen embryo transfer, an interval of 1-2 menstrual cycles after the retrieval cycle is needed for endometrial preparation using an artificial or natural cycle, extending the overall timeline by 2-3 months.
Suitable Candidates: Who Should Consider IVM
- Patients with Polycystic Ovary Syndrome (PCOS), especially those with AMH > 5 ng/mL, antral follicle count > 20, previous OHSS or high OHSS risk
- Individuals allergic to or experiencing severe adverse reactions to ovulation induction medications (FSH, hMG, etc.) such as headaches, bloating, or mood swings significantly affecting daily life
- Those with previous conventional IVF cycles showing asynchronous follicle development, very low oocyte yield (< 3) but normal ovarian reserve
- Cancer patients requiring urgent fertility preservation (IVM cycle is short, independent of hormonal stimulation, and can be performed quickly)
- Individuals with a history of estrogen-sensitive tumors (e.g., breast cancer, endometrial cancer) needing to avoid high estrogen environments
Unsuitable Candidates: Who Should Be Cautious or Avoid IVM
- Advanced age (≥ 40 years), diminished ovarian reserve (AMH < 1.0 ng/mL, antral follicle count < 5) — low oocyte yield, poor maturation rates, unfavorable clinical outcomes
- Previous IVM cycles with complete oocyte maturation failure or very low fertilization rate (< 20%)
- Infertility due to endometrial factors (e.g., intrauterine adhesions, endometrial tuberculosis, Asherman's syndrome) — endometrial issues should be addressed first
- Untreated thyroid dysfunction, hyperprolactinemia, or other endocrine disorders
- Severe adenomyosis or endometriosis (Stage IV) — IVM does not improve endometrial receptivity
Frequently Asked Questions: Top 5 Patient Queries
Q1: Will the oocytes definitely mature after IVM retrieval?
Not necessarily. The overall maturation rate is about 60%-75%, reaching over 70% in PCOS patients and around 65% in those with normal ovarian reserve. Maturation failure occurs in about 15%-25% of cases, and those oocytes cannot be used for ICSI. Before treatment, the doctor will assess maturation potential based on your AMH, antral follicles, and previous oocyte morphology, but a 100% guarantee cannot be given.
Q2: Is the quality of IVM embryos inferior to conventional IVF embryos?
Current studies show no significant difference in morphological grading between IVM-derived and conventional IVF embryos, but the blastocyst formation rate is slightly lower (approx. 35% vs 45%). PGT-A results have not shown a significantly higher aneuploidy rate in IVM embryos. However, more follow-up data are needed to evaluate the long-term developmental potential of IVM embryos.
Q3: What documents are needed for IVM in Hong Kong?
Mainland Chinese residents traveling to Hong Kong for IVM need to provide: ① Valid Exit-Entry Permit for Travelling to and from Hong Kong and Macau (with valid endorsement); ② Marriage certificate (Hong Kong law requires assisted reproduction for legally married couples); ③ Identity card; ④ Initial medical records and previous test reports (recommended to be translated into English or Traditional Chinese in advance). Some centers may require infectious disease screening reports (HIV, Hepatitis B, Hepatitis C, Syphilis) from within the last 3 months.
Q4: What dietary and lifestyle precautions should be taken during an IVM cycle?
Before retrieval: Eat a normal diet, avoid strenuous exercise and sexual intercourse. After retrieval: Rest well, avoid actions that increase abdominal pressure, drink plenty of water, monitor urine output and abdominal pain. After transfer: Resume normal activities, avoid prolonged bed rest, supplement with folic acid and vitamin D appropriately. No special dietary supplements are needed.
Q5: Is IVM covered by medical insurance?
Assisted reproductive treatments in Hong Kong are not covered by public hospital medical insurance and must be self-funded. In Mainland China, IVM is currently not in the medical insurance reimbursement catalog (except for pilot programs in some provinces/cities). Patients should prepare their budget in advance.
From a Practitioner's Perspective: The True Clinical Status of IVM
As a reproductive specialist, I have observed IVM's journey over the past decade from "overhyped expectations" to "returning to a reasonable position." Early on, some centers promoted it as a "more natural IVF technology," leading to inflated patient expectations. In reality, IVM is a complementary technology, not a mainstream one. For PCOS patients, it offers a safe path to avoid OHSS, but pregnancy rates are indeed lower than conventional IVF. In non-PCOS populations, the advantages of IVM are less pronounced, and conventional IVF remains the first choice.
Hong Kong's IVM clinical pathways are relatively mature, with technical exchange between centers. However, patients need to understand: choosing IVM means accepting a lower pregnancy rate in exchange for higher safety and less medication exposure. Whether this trade-off is worthwhile depends on your personal health status, risk tolerance, and treatment history.
Risk Reminder
IVM is not a risk-free technology. Oocyte retrieval puncture carries a 0.1%-0.3% risk of bleeding, infection, and damage to adjacent organs, similar to conventional IVF. The impact of the in vitro maturation process on oocyte epigenetic modifications is still under investigation. No significant increase in birth defect risk has been found to date, but long-term follow-up data are limited. It is recommended to thoroughly discuss the risk-benefit ratio with your doctor before treatment and sign an informed consent form.
Checklist Reminder
Before deciding on IVM treatment, ensure the following tests have been completed: ① Baseline endocrine tests (FSH, LH, E2, AMH, TSH, PRL on cycle day 2-4); ② Transvaginal ultrasound (antral follicle count, endometrial morphology, exclusion of ovarian cysts and fibroids); ③ Semen analysis for the male partner (at least 2 times); ④ Infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis for both partners); ⑤ Karyotype analysis (both partners, especially if there is a history of miscarriage or family genetic disorders). It is advisable to keep all original test reports for review by the Hong Kong center.
Time Planning Reminder
Hong Kong IVM treatment from initial consultation to transfer takes about 4-6 weeks, provided the patient has passed the evaluation and successfully scheduled an appointment. It is recommended to complete the following 2-3 months in advance: ① Apply for or renew the Exit-Entry Permit for Travelling to and from Hong Kong and Macau (with valid endorsement); ② Organize and translate previous medical records; ③ Confirm the initial consultation time and required documents with the Hong Kong center; ④ Arrange work and personal life, reserving at least 2 weeks of leave (1 week before and 1 week after retrieval). If planning a frozen embryo transfer, the overall timeline extends to 3-5 months.
Special Populations Reminder
The following groups need extra caution when choosing IVM: ① Age ≥ 38 years: pregnancy rates drop significantly; conventional IVF or egg donation should be considered first. ② BMI > 30 kg/m²: IVM pregnancy rates are lower than in normal-weight individuals, and anesthesia risks are higher; weight loss is recommended first. ③ History of recurrent miscarriage: IVM does not reduce miscarriage risk; a full recurrent miscarriage workup should be completed before deciding. ④ Genetic diseases requiring PGT-M: the limited number of embryos obtained from IVM may not meet PGT testing requirements; individualized assessment is needed.
Doctor's Advice
If you are considering Hong Kong IVM treatment, my advice is: First, confirm whether you belong to the advantageous group for IVM (PCOS, high OHSS risk, medication intolerance). If not, conventional IVF may be a more efficient choice. Second, choose a fertility center and embryologist with specific IVM experience; this technology demands higher laboratory capabilities than conventional IVF. Third, manage your expectations—the goal of IVM is to achieve pregnancy safely, not to pursue the highest success rate. Fourth, complete all necessary tests before treatment to avoid back-and-forth trips due to incomplete documentation. Fifth, maintain open communication with your doctor to understand the risks and alternatives at each step.
This article is compiled based on general knowledge and clinical practice in the assisted reproductive industry and does not constitute personal medical advice. Treatment plans should be formulated by qualified reproductive specialists based on the patient's specific condition. Data are sourced from publicly available medical literature and statistics from the International IVM Collaborative Group and are for reference only.
0 comments